313 related articles for article (PubMed ID: 17169777)
1. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
Lévy F; Colombetti S
Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
[TBL] [Abstract][Full Text] [Related]
2. DC-based cancer vaccines: lessons from clinical trials.
Brody JD; Engleman EG
Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
[No Abstract] [Full Text] [Related]
3. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
4. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
5. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
6. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
9. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
11. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
Slovin SF
Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
[TBL] [Abstract][Full Text] [Related]
13. Cancer vaccines: a critical review on clinical impact.
Bitton RJ
Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
[TBL] [Abstract][Full Text] [Related]
14. Cancer vaccines: challenges and outlook in the field.
Paul S; Acres B; Limacher JM; Bonnefoy JY
IDrugs; 2007 May; 10(5):324-8. PubMed ID: 17487784
[TBL] [Abstract][Full Text] [Related]
15. How much help does a vaccine-induced T-cell response need?
Weber JS; Mulé JJ
J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
[No Abstract] [Full Text] [Related]
16. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
17. [Peptide-based vaccine therapy for cancer patients].
Yamada A
Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
[No Abstract] [Full Text] [Related]
18. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
19. Antitumor resistance formation in animals in early neonatal period.
Kazmin SD; Todor IN; Chekhun VE
J Exp Clin Cancer Res; 2007 Mar; 26(1):83-90. PubMed ID: 17550136
[TBL] [Abstract][Full Text] [Related]
20. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]